Edgewise Therapeutics, Inc. (EWTX) earnings
EWTX earnings moved a median of -1.01% by the close. Quarterly and annual EWTX reports and results, each read against the price at its own news timestamp. Back to the EWTX overview →
21 measured EWTX earnings events.
Where these EWTX earnings landedvs 21 measured EWTX earnings reactions
| Middle 50% of EWTX earnings reactions | -6.37% to +1.31% |
|---|---|
| Median reaction (to close) | -1.01% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 EWTX earnings events with a measured close landed between -6.37% and +1.31%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | Press release | +0.79% | +0.66% | |
| Form 10-Q Edgewise Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.79% | +0.66% | |
| Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications | Press release | -3.97% | -6.37% | |
| Form 10-Q Edgewise Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.97% | -6.37% | |
| Form 10-K Edgewise Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.57% | -0.80% | |
| Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | -0.17% | -2.84% | |
| Form 10-Q Edgewise Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.17% | -2.84% | |
| Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | Press release | -2.23% | -6.90% | |
| Form 10-Q Edgewise Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.23% | -6.90% | |
| Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | Press release | +1.15% | +1.31% | |
| Form 10-Q Edgewise Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.15% | +1.31% | |
| Form 10-K Edgewise Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.17% | -1.01% | |
| Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | -0.68% | -3.59% | |
| Form 10-Q Edgewise Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.68% | -3.59% | |
| Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Press release | -0.75% | +1.70% | |
| Form 10-Q Edgewise Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.75% | +1.70% | |
| Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | Press release | +5.19% | +1.78% | |
| Form 10-Q Edgewise Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +5.19% | +1.78% | |
| Form 10-K Edgewise Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.74% | -0.80% | |
| Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights | Press release | -2.87% | -8.77% | |
| Form 10-Q Edgewise Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.87% | -8.77% |
Keep exploring
More EWTX: analyst actions → · SEC filings → · EWTX overview →